Prevalence and clinical impact of obesity in patients living with type 1 diabetes

Nora Boutatss; Haraj Nassim Essabah; Aziz Siham El; Asma Chadli

doi:10.1530/endoabs.110.EP382

EP382

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP382 | DOI: 10.1530/endoabs.110.EP382

ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)

Prevalence and clinical impact of obesity in patients living with type 1 diabetes

Nora Boutatss ¹ , Nassim Essabah Haraj ¹ , Siham El Aziz ¹ & Asma Chadli ¹

Author affiliations

¹UHC Ibn Rochd, Department of Endocrinology and Metabolic Diseases Ibn Rochd University Hospital - Casablanca, Morocco Laboratory of Clinical Neurosciences and Mental Health Faculty of Medicine and Pharmacy - Hassan II University - Casablanca, Morocco

JOINT3904

Introduction: Although traditionally linked to type 2 diabetes, obesity is becoming increasingly prevalent among patients living with type 1 diabetes.

Objective: To assess the prevalence of obesity in T1D patients and identify associated factors, guiding prevention and management strategies.

Materials and Methods: A retrospective descriptive study was conducted on 755 T1D patients followed in the our department. Obesity was defined as a body mass index (BMI) greater than 30 kg/m². The data are analyzed using the IBM SPSS Statistics 27.0 software

Results: The study included 755 patients with a mean age of 25.7 ± 9.5 years and an average HbA1c of 12.48 ± 2.6%. The prevalence of overweight and obesity was 20.2% and 8.1%, respectively. Women accounted for 67% of obese patients, with a male-to-female ratio of 0.3 among obese individuals (P = 0.02). Hypertension (HTN) prevalence was significantly higher in obese patients (44.5%) compared to normal-weight individuals (18.9%, P< 0.01). Dyslipidemia was more frequent in obese patients (32.7%) than in non-obese patients (12.3%, P = 0.02). Retinopathy was observed in 26% of obese patients compared to 17.3% in normal-weight patients. Furthermore, 66% of obese patients were using human insulin.

Conclusion: Our study highlights specific and modifiable risk factors in obese T1D patients, including associations with cardiovascular and microvascular comorbidities. A proactive approach, incorporating lifestyle interventions and personalized management, is essential for optimal care.